Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients Chronically Infected With Hepatitis C Virus (HCV) Who Are Non-Responders or Relapsers After Treatment With Pegylated Interferon Plus Ribavirin

NCT00128271 is registered in ClinicalTrials.gov with Peregrine Pharmaceuticals as lead sponsor.

NCT NCT00128271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients Chronically Infected With Hepatitis C Virus (HCV) Who Are Non-Responders or Relapsers After Treatment With Pegylated Interferon Plus Ribavirin
Lead sponsor
Peregrine Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2005
Completion date
Not reported
Enrollment
32
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c